Harvard Bioscience, Inc.
HBIO
$0.76
$0.011.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 46.06% | 95.47% | -279,766.67% | 100.37% | -64.06% |
| Total Depreciation and Amortization | -18.07% | -2.36% | -5.97% | -3.03% | 0.78% |
| Total Amortization of Deferred Charges | 70.00% | 60.31% | 33.67% | 10.11% | 27.14% |
| Total Other Non-Cash Items | -18.48% | -99.12% | 10,766.06% | -71.07% | -14.54% |
| Change in Net Operating Assets | -89.60% | -20.59% | 692.24% | -212.31% | 133.46% |
| Cash from Operations | -60.65% | -7.74% | 73.10% | 304.87% | 0.47% |
| Capital Expenditure | -132.58% | 82.65% | -70.43% | 65.80% | -7.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.08% | 15.29% | -3.03% | 28.57% | -118.10% |
| Cash from Investing | -49.36% | 65.89% | -46.57% | 58.06% | -342.58% |
| Total Debt Issued | -- | -- | -- | -100.00% | 6.56% |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | 0.00% | 67.21% |
| Issuance of Common Stock | -100.00% | -- | -- | 973.33% | -92.06% |
| Repurchase of Common Stock | -- | 100.00% | 85.52% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 16.45% | -135.66% | -- | 100.00% | -- |
| Cash from Financing | -1.59% | -4.49% | 11.27% | -164.50% | 1,088.70% |
| Foreign Exchange rate Adjustments | -113.13% | 86.43% | 193.39% | -198.11% | 9,150.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -132.96% | 31.85% | 411.93% | -188.48% | 351.69% |